Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Le résumé fourni par la source

Sorafenib, a multi-kinase inhibitor agent, has been used in hepatocellular carcinoma (HCC) treatment for almost one and a half decades.It was the gold standard treatment based on two randomized Phase III trials.1,2 Sorafenib remained the only agent used in systemic therapy from 2008 to 2017.However, since then, many agents, including tyrosine kinase inhibitors, vascular endothelial growth factor-targeted therapies, and immune checkpoint inhibitors alone or in combination have been approved for systemic treatment.Regorafenib was approved for second-line treatment by the RESOURCE trial in 2017, while lenvatinib was approved for the first-line treatment by the REFLECT trial in 2018.3,4 In the recently published Phase III IMBrave150 trial, atezolizumab and bevacizumab combination treatments

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.